Whitehawk Therapeutics, Inc.
WHWK · United States
Share price · WHWK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when WHWK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Oct 2026-10.7%
Nothing announced by WHWK that day or the session before.
- 6 Aug 2026+15.5%
- 13 May 2026+25.8%
- 16 Apr 2026+8.5%
- 14 Apr 2026+15.3%
Nothing announced by WHWK that day or the session before.
- 27 Mar 2026-11.5%
Nothing announced by WHWK that day or the session before.
- 5 Mar 2026+9.8%
Nothing announced by WHWK that day or the session before.
- 27 Feb 2026+8.0%
- 4 Dec 2025+14.3%
Nothing announced by WHWK that day or the session before.
Share of unusual movement by asset
For each asset, the share of WHWK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
HWK-007events and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 34% |
| Sessions with no dated event | — | 65% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | PTK7 (protein tyrosine kinase 7)Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $18M | $69M+ $101M short-term inv. | $21M-$20M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $13M | $85M+ $105M short-term inv. | $17M-$15M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $17M | $35M+ $88M short-term inv. | $22M-$22M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $14M | $38M+ $125M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $49M | $145M+ $32M short-term inv. | $53M-$53M operating cash flow | report ↗ |
| 2025-Q1 | $7.2M | $8.8M | $228M+ $3.5M short-term inv. | —-$12M operating cash flow | report ↗ |
| 2024-Q3 | $7.2M | $10M | $31M+ $32M short-term inv. | $13M-$16M operating cash flow | report ↗ |
| 2024-Q2 | $6.2M | $13M | $41M+ $37M short-term inv. | $15M-$9.2M operating cash flow | report ↗ |
| 2024-Q1 | $5.3M | $14M | $54M+ $34M short-term inv. | $18M-$20M operating cash flow | report ↗ |
| 2023-Q3 | $6.0M | $12M | $69M+ $51M short-term inv. | $16M-$12M operating cash flow | report ↗ |
| 2023-Q2 | $6.2M | $13M | $68M+ $67M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2023-Q1 | $5.9M | $11M | $34M+ $117M short-term inv. | $15M-$21M operating cash flow | report ↗ |
| 2022-Q3 | $4.3M | $8.8M | $135M+ $48M short-term inv. | $14M-$8.2M operating cash flow | report ↗ |
| 2022-Q2 | $3.4M | $7.7M | $119M | $18M-$11M operating cash flow | report ↗ |
| 2022-Q1 | $2.3M | $6.8M | $130M | $14M-$19M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $5.8M | $161M | $87M-$4.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $7.2M | $91M | $38M+ $108M short-term inv. | $5.2M-$97M operating cash flow | report ↗ |
Whitehawk Therapeutics reported full-year 2025 revenue of $7.15M, down 72.5% YoY, with R&D spend of $90.96M, up 78.2% YoY. Cash and cash equivalents were $37.57M, and total cash, cash equivalents and short-term investments were $145.7M at year-end 2025. The company reported a full-year net loss of $20.6M, which included an $87.3M gain on the divestiture of AADI Subsidiary, and a quarterly net burn of $20.6M.
The company guided that its cash position is anticipated to fund operations into 2028. Phase 1 trials for PTK7-targeted ADC HWK-007 and MUC16-targeted ADC HWK-016 are actively recruiting, with initial results expected in 1H 2027, and HWK-206 is on track for an IND submission in mid-2026 with a Phase 1 start in Q3 2026. Whitehawk also announced the appointment of Margaret Dugan, MD as Chief Medical Officer and presented real-world data supporting PTK7 as a broadly expressed tumor target.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $26M | $51M | $29M+ $19M short-term inv. | $16M-$60M operating cash flow | report ↗ |
| 2023-FY | $24M | $49M | $63M+ $46M short-term inv. | $16M-$60M operating cash flow | report ↗ |
| 2022-FY | $15M | $33M | $39M+ $134M short-term inv. | $15M-$50M operating cash flow | report ↗ |
| 2021-FY | $1.1M | $20M | $149M+ $0 short-term inv. | $28M-$22M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 14 sales ($2.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-15 | Giacobello Scott M. · CHIEF FINANCIAL OFFICER | Award / grant (derivative) | 118,476 | — | — | Form 4 |
| 2026-09-15 | Dugan Margaret · Chief Medical Officer | Award / grant (derivative) | 81,250 | — | — | Form 4 |
| 2026-09-15 | Lennon David James · director, CHIEF EXECUTIVE OFFICER | Award / grant (derivative) | 193,957 | — | — | Form 4 |
| 2026-09-15 | Dornan David · Chief Scientific Officer | Award / grant (derivative) | 85,887 | — | — | Form 4 |
| 2026-09-15 | BALL BRYAN · See remarks | Award / grant (derivative) | 91,633 | — | — | Form 4 |
| 2026-09-15 | Giacobello Scott M. · CHIEF FINANCIAL OFFICER | Award / grant (derivative) | 118,476 | — | — | Form 4 |
| 2026-09-15 | Dugan Margaret · Chief Medical Officer | Award / grant (derivative) | 81,250 | — | — | Form 4 |
| 2026-09-15 | Lennon David James · director, CHIEF EXECUTIVE OFFICER | Award / grant (derivative) | 193,957 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 62 reporting institutions held 35.2M shares ($122.4M, 59.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | QVT Financial LP | 4,615,709 | $15.9M |
| 2 | ORBIMED ADVISORS LLC | 4,166,000 | $14.4M |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 3,700,000 | $12.8M |
| 4 | ACUTA CAPITAL PARTNERS, LLC | 3,410,402 | $11.8M |
| 5 | Avoro Capital Advisors LLC | 2,849,402 | $9.8M |
| 6 | KVP Capital Advisors, LP | 2,165,997 | $7.5M |
| 7 | Siren, L.L.C. | 2,082,000 | $7.2M |
| 8 | Yu Fan | 2,070,000 | $7.1M |
| 9 | STEMPOINT CAPITAL LP | 1,878,738 | $6.5M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 1,315,770 | $4.5M |
| 11 | ACORN CAPITAL ADVISORS, LLC | 1,139,363 | $3.9M |
| 12 | Ally Bridge Group (NY) LLC | 817,939 | $2.8M |
| 13 | Balyasny Asset Management L.P. | 550,441 | $1.9M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 457,540 | $1.6M |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 428,622 | $1.5M |